In a stratified analysis for stage IC/IIEC, combined positivity identified a subset of patients with a significantly longer OCSS in the discovery cohort but only a non-significant trend in the validation cohort.
However, the five-year ovarian cancer specific survival among women with ER positive stage IC/IIEC was 89.0% (standard error 3.3%) and for PR positive tumors 89.9% (standard error 3.2%), robustly below the 95% threshold where adjuvant therapy could be avoided.